Facilitated By

San Antonio Medical Foundation

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy And Safety Study Of Topically Administered LUT014 In Metastatic Colorectal Cancer Patients With EGFR Inhibitor Induced Acneiform Lesions

Brooke Army Medical Center

Brooke Army Medical Center (BAMC) at Fort Sam Houston, Texas, is proud to provide safe, quality care to our military service members, their families, veterans and civilian emergency patients as the most robust and productive healthcare organization within the Military Health System (MHS).

Principal Investigator(s)
Email for information
Funded by
Geneva
Research Start Date
Status
Active

The primary objective of this study is to evaluate the efficacy of two (2) strengths of LUT0 14 Gel [0.3 mg/g (0.03% weight/weight, w/w) and 1.0 mg/g (0.10% w/w)] topically applied once a day (qd) for four (4) weeks in metastatic colorectal cancer (mCRC) patients with epidennal growth factor receptor inhibitor (EGFRI) induced Grade 2 acneifonn lesions compared to placebo.

Collaborative Project
Clinical Care
Infectious Disease
The appearance of name-brand products in this article does not constitute endorsement by Brooke Army Medical Center, the U.S. Army Medical Center, the U.S. Army Medical Department, the U.S. Army Office of the Surgeon General, the Department of the Army, the Department of Defense, or the U.S. Government of the information, products, or services contained therein.